Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.55 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: metformin, metformin hydrochloride, me-344 | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 2 Parkinson's papers of 54 | 0.85 |
| pathways Reactome | 2 pathways; mostly mitochondrial quality control | 1.00 |
Knock down and overexpress NDUFB9 in a dopamine neuron, astrocyte and microglia tri-culture; measure PINK1–parkin mitophagy flux (mt-Keima) and phospho-ubiquitin (pS65-Ub) and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- PINK1–parkin mitophagy flux (mt-Keima) and phospho-ubiquitin (pS65-Ub)
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves PINK1–parkin mitophagy flux (mt-Keima) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of NDUFB9 in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: PINK1–parkin mitophagy flux (mt-Keima) and phospho-ubiquitin (pS65-Ub); dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Earlier readings: 2026-10-26 0.58; 2026-10-25 0.58; 2026-10-24 0.58; 2026-10-23 0.58.
Sealed predictions
- NDUFB9 in dopamine neurons, braak+0.77 (p 0.015) → -0.45 (p 0.219)receipt 0593
- NDUFB9 in dopamine neurons, braak-0.13 (p 0.399) → +0.09 (p 0.560)receipt 0138
- NDUFB9 in dopamine neurons, resilience+0.14 (p 0.670) → -0.10 (p 0.683)receipt 0139
Swarm cases
receipt 0593: NDUFB9 in dopamine neurons, braak
- power
- full sample +0.13 (p 0.603, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.15 (p 0.549, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.17 (p 0.504, n 18). could be the mix.
- skeptic
- leave-one-out range +0.07 to +0.29, sign flips 0; without severely affected donors +0.13 (p 0.603, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NDUFB9 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0139: NDUFB9 in dopamine neurons, resilience
- power
- full sample -0.02 (p 0.916, n 55), 95% CI -0.28 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for age, sex and PMI: +0.02 (p 0.916, n 55). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.12 (p 0.542); controlling for it: -0.03 (p 0.866, n 55). could be the mix.
- skeptic
- leave-one-out range -0.10 to +0.07, sign flips 10; without severely affected donors -0.06 (p 0.748, n 46). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for NDUFB9 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0138: NDUFB9 in dopamine neurons, braak
- power
- full sample -0.02 (p 0.841, n 84), 95% CI -0.24 to +0.19. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: -0.03 (p 0.769, n 84). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis -0.72 (p 1.8e-14); controlling for it: +0.02 (p 0.840, n 84). could be the mix.
- skeptic
- leave-one-out range -0.05 to +0.01, sign flips 4; without severely affected donors +0.03 (p 0.784, n 75). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NDUFB9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts